Psilocybin is under clinical development by Filament Health and currently in Phase I for Major Depressive Disorder.

Psilocybin is under clinical development by Filament Health and currently in Phase I for Substance (Drug) Abuse.

Clinics offering ketamine infusions and injections for “treatment-resistant depression” are today claiming 24-48 hours ...

Discover why psychiatrists are moving beyond single-treatment approaches and how combining therapies could be the key to ...

Glutamatergic medications showed promise in treating obsessive-compulsive and related disorders (OCRDs), especially obsessive ...